Myocardial Injury From Catecholamine Excess: Mechanisms, Clinical Manifestations, and Management

Abstract

Myocardial injury resulting from catecholamine excess represents a clinically significant and multifaceted phenomenon encountered in diverse acute and chronic medical contexts. Characterized by direct and indirect deleterious effects on myocardial tissue, this condition may arise from endogenous surges in catecholamines, as seen in pheochromocytoma, stress-related cardiomyopathies, or exogenous administration of sympathomimetic agents. This review explores the epidemiology, pathophysiological mechanisms, risk factors, diagnostic strategies, clinical presentations, and evidence-based management of catecholamine-induced myocardial injury. It further discusses recent advances, guideline recommendations, and practical implications for healthcare professionals aiming to optimize cardiovascular outcomes in affected patients.

Introduction

Catecholamine excess, whether endogenous or iatrogenic, is increasingly recognized as a pivotal mediator of acute and chronic myocardial injury. The clinical spectrum includes stress-induced (Takotsubo) cardiomyopathy, myocardial ischemia, arrhythmias, and, in severe cases, acute heart failure or cardiogenic shock. Understanding the nuances of catecholamine-mediated myocardial toxicity, including molecular mechanisms, clinical patterns, and therapeutic strategies, is critical for clinicians across emergency, critical care, cardiology, and endocrinology settings.

Epidemiology / Disease Burden

The incidence of myocardial injury secondary to catecholamine excess is challenging to quantify due to underrecognition, heterogeneous etiologies, and overlap with other cardiovascular disorders. Stress-induced cardiomyopathy accounts for approximately 1-2% of patients presenting with suspected acute coronary syndrome, with a higher prevalence among postmenopausal women. Pheochromocytoma-induced cardiac complications occur in roughly 10-20% of cases, and iatrogenic injury from catecholaminergic drugs remains a pertinent concern in intensive care. The true burden is likely underestimated, underscoring the need for heightened clinical vigilance and standardized diagnostic criteria.

Pathophysiology

Catecholamine excess exerts its toxic myocardial effects through complex and multifactorial mechanisms. Direct stimulation of beta-adrenergic receptors amplifies intracellular cyclic AMP and calcium influx, precipitating myocyte hypercontractility, metabolic demand, and eventual cellular necrosis. High catecholamine levels promote oxidative stress, mitochondrial dysfunction, and microvascular spasm, leading to myocardial stunning and contraction band necrosis. Indirect effects include coronary vasoconstriction, increased afterload, and arrhythmogenicity. The interplay between these mechanisms results in heterogeneous patterns of myocardial injury, ranging from reversible dysfunction to irreversible necrosis.

Risk Factors

Several patient- and disease-specific factors modulate susceptibility to catecholamine-induced myocardial injury. These include pre-existing cardiovascular disease, hypertension, advanced age, female sex (notably in Takotsubo cardiomyopathy), underlying endocrine disorders such as pheochromocytoma or paraganglioma, and exposure to high-dose sympathomimetic agents. Acute physical or emotional stress, sepsis, and neurologic insults (e.g., subarachnoid hemorrhage) also serve as potent triggers of catecholamine surges. Genetic polymorphisms affecting adrenergic receptor sensitivity may further influence individual risk profiles.

Clinical Features

The clinical manifestations of catecholamine-mediated myocardial injury are diverse, reflecting the extent and distribution of myocardial involvement. Patients may present with acute chest pain, dyspnea, palpitations, syncope, or cardiogenic shock. Electrocardiographic findings often mimic acute myocardial infarction, including ST-segment changes and T-wave inversions. In Takotsubo cardiomyopathy, characteristic regional wall motion abnormalities (apical ballooning) are observed without obstructive coronary disease. Arrhythmias, heart failure, and sudden cardiac death may complicate severe cases. Recognition of catecholamine excess as the underlying etiology is critical for guiding management.

Diagnosis

Diagnosis of catecholamine-induced myocardial injury hinges on a combination of clinical suspicion, laboratory markers, imaging, and exclusion of alternative etiologies. Cardiac biomarkers (troponin, BNP/NT-proBNP) are typically elevated, reflecting myocyte injury and stress. Echocardiography reveals regional or global systolic dysfunction, while cardiac MRI may demonstrate myocardial edema and late gadolinium enhancement consistent with necrosis or fibrosis. Coronary angiography is often necessary to exclude obstructive coronary disease, particularly in patients with acute coronary syndrome presentations. In suspected pheochromocytoma, plasma or urinary metanephrines confirm catecholamine excess. Emerging modalities, such as strain imaging and molecular biomarkers, offer promise for earlier detection and risk stratification.

Treatment & Management

Management of catecholamine-induced myocardial injury is multifaceted and tailored to the underlying etiology and clinical severity. Initial stabilization includes hemodynamic support, oxygenation, and judicious use of vasopressors or inotropes. Beta-blockers are the mainstay in most settings, mitigating adrenergic toxicity and arrhythmias, but should be used with caution in acute heart failure. Alpha-blockers are essential in pheochromocytoma to control hypertension and prevent crises. In Takotsubo cardiomyopathy, supportive care with heart failure therapy is indicated; most patients recover systolic function within weeks. Mechanical circulatory support may be required for refractory shock. Prompt identification and cessation of exogenous catecholamine sources are critical. Multidisciplinary care, including cardiology, endocrinology, and critical care input, optimizes outcomes.

Recent Advances / Emerging Therapies

Recent advances in our understanding of catecholamine-induced myocardial injury include the identification of novel molecular pathways, such as microRNA regulation and mitochondrial bioenergetics, offering potential therapeutic targets. The use of selective beta-blockers, mineralocorticoid receptor antagonists, and antioxidants is under investigation for cardioprotection. Cardiac MRI is increasingly utilized for early detection and prognostication. Ongoing clinical trials are exploring the role of neprilysin inhibitors and SGLT2 inhibitors in stress cardiomyopathy. Personalized approaches, including genetic profiling and individualized risk stratification, represent the frontier of future management.

Guideline Recommendations

Current guidelines advocate a high index of suspicion for catecholamine-induced myocardial injury in patients presenting with acute heart failure or myocardial dysfunction without clear coronary etiology, particularly in the setting of stress, endocrinopathies, or catecholaminergic drug exposure. Echocardiography and cardiac MRI are recommended for diagnosis and follow-up. In pheochromocytoma, preoperative alpha-blockade is mandatory. Beta-blockers are advised for arrhythmia control and in select cases of stress cardiomyopathy. Multidisciplinary collaboration and individualized care plans are key to optimizing patient outcomes.

Conclusion

Myocardial injury resulting from catecholamine excess is a clinically significant and potentially reversible entity with diverse etiologies and presentations. Advances in diagnostic imaging, biomarker discovery, and mechanistic understanding have enhanced recognition and management. Early diagnosis, tailored therapy, and multidisciplinary care are essential to mitigate morbidity and mortality. Ongoing research into molecular mechanisms and emerging therapies holds promise for improved prevention and treatment strategies in this complex clinical domain.